Trials / Completed
CompletedNCT04906850
Evaluation of the New Variant 501Y.V2 of COVID-19
Comparison of Mortality in Severe SARS-Cov-2 Infection Caused by the 501Y.V2 Variant and B.1.1.7 Variant
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (actual)
- Sponsor
- Centre Hospitalier Régional Metz-Thionville · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
In January 2021, the incidence of COVID-19-and its mortality started rising for the third time in France. This rise may associate with three emerging variants, namely, V1, V2, and V3, which are the 20I/501Y.V1 ("English"), 20H/501Y.V2 ("South African"), and 20J/501Y.V3 ("Brazilian") variants, respectively. V1 was recently suggested to increase mortality in people in the United Kingdom who tested positive for COVID-19 on community screening. Very little is known about V2 infection, including its outcomes relative to other strains. In early 2021, V2 spread to the Grand-Est region (northeastern France). Here, the investigators aimed to report mortality data of patients admitted in ICU between February and April 2021 in 3 hospitals in Grand-Est: Metz, Thionville and Nancy.
Conditions
Timeline
- Start date
- 2021-03-01
- Primary completion
- 2021-04-15
- Completion
- 2021-05-15
- First posted
- 2021-05-28
- Last updated
- 2021-06-02
Locations
2 sites across 1 country: France
Source: ClinicalTrials.gov record NCT04906850. Inclusion in this directory is not an endorsement.